

Functional Profiling of Rheumatoid Arthritis Reveals Disease-Specific Immunomodulatory Responses and Novel Therapeutic Targets
Apr 16, 2026
Boudesco et al
Now reading:
Functional Profiling of Rheumatoid Arthritis Reveals Disease-Specific Immunomodulatory Responses and Novel Therapeutic Targets
Author
Boudesco et al
Date
Apr 16, 2026
4/16/26
Today's RA therapies only slow disease. The next generation needs to cure it, and that first requires a comprehensive map of immune dysfunction, which is exactly what we're working to build.
At IMMUNOLOGY2026, Graph's co-founder and VP Immunology Christophe Boudesco presented the latest results from Graph's Functional Immune Manifold (FIM): a platform that fuses functional perturbation of patient immune cells with multi-omics data to map immune dysfunction and uncover clinically positioned, therapeutically tractable biology in immune diseases.
The crux of our work is a generalized approach that merges large-scale functional profiling with sparse transcriptomic data. By combining functional responses with existing priors, we identify context-dependent, biomarker-stratified targets - the kind built for curative intent, not chronic management.
It's a patient-first, clinically linked approach to I&I discovery. And we're quickly advancing candidates into validation.
View our full poster here
Today's RA therapies only slow disease. The next generation needs to cure it, and that first requires a comprehensive map of immune dysfunction, which is exactly what we're working to build.
At IMMUNOLOGY2026, Graph's co-founder and VP Immunology Christophe Boudesco presented the latest results from Graph's Functional Immune Manifold (FIM): a platform that fuses functional perturbation of patient immune cells with multi-omics data to map immune dysfunction and uncover clinically positioned, therapeutically tractable biology in immune diseases.
The crux of our work is a generalized approach that merges large-scale functional profiling with sparse transcriptomic data. By combining functional responses with existing priors, we identify context-dependent, biomarker-stratified targets - the kind built for curative intent, not chronic management.
It's a patient-first, clinically linked approach to I&I discovery. And we're quickly advancing candidates into validation.
View our full poster here
Read More
Functional Profiling of Rheumatoid Arthritis Reveals Disease-Specific Immunomodulatory Responses and Novel Therapeutic Targets
Functional Profiling of Rheumatoid Arthritis Reveals Disease-Specific Immunomodulatory Responses and Novel Therapeutic Targets
Research
Apr 16, 2026
4/16/26
Functionally-Guided Multiomics Profiling of Human Systemic Inflammation Identifies Myeloid Therapeutic Targets
Functionally-Guided Multiomics Profiling of Human Systemic Inflammation Identifies Myeloid Therapeutic Targets
Research
Jan 28, 2026
1/28/26
Graph partners with Parse Biosciences
Graph partners with Parse Biosciences
News
Jan 20, 2026
1/20/26
First data in RA - Cytodata 2025
First data in RA - Cytodata 2025
Research
Dec 11, 2025
12/11/25
Data Foundations of Precision Immunology
Data Foundations of Precision Immunology
Article
Nov 24, 2025
11/24/25
Graph and BIIE announce strategic collaboration to in precision immunology
Graph and BIIE announce strategic collaboration to in precision immunology
News
Oct 7, 2025
10/7/25
Graph awarded €1.1M Deep Tech Grant
Graph awarded €1.1M Deep Tech Grant
News
Apr 22, 2025
4/22/25
GTX co-founder appointed as Faculty Professor at the BIIE
GTX co-founder appointed as Faculty Professor at the BIIE
News
Mar 28, 2025
3/28/25
Graph Awarded €1.1M "Austrian Life Sciences" FFG Grant
Graph Awarded €1.1M "Austrian Life Sciences" FFG Grant
News
Mar 3, 2025
3/3/25
Graph Raises $3.1M Pre-Seed Round
Graph Raises $3.1M Pre-Seed Round
News
Dec 10, 2024
12/10/24
Copyright GraphTx 2026
Vienna, Asutria
Vienna, Austria
All system opperational